Expert in the physiological delivery of insulin, Defymed intends to expand its scope of action to other therapeutic applications, such as the delivery of antibiotics or chemotherapy by a minimally invasive route of delivery.
The deLIVER project developed by Defymed aims to:
Improvement of ExOlin® device to develop a mini-invasive surgery
Targeted and physiological delivery shall increase efficacy of drugs
Exploration of drug delivery in other diseases
The global market of innovative drug delivery devices was evaluated at $178.8 billion in 2015
Confirm Defymed’s position as worldwide leader for the development of physiological drug delivery device